Hematin therapy in porphyric attacks

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 1980 English Publisher:Springer Science and Business Media LLCJournal:Klinische Wochenschrift, volume 58, pages 829-832 (issn: 0023-2173, eissn: 1432-1440,

Copyright policy )

Authors: C A, Pierach; I, Bossenmaier; R, Cardinal; M, Weimer; C J, Watson;

doi: 10.1007/bf01491103

pmid: 7453089

Hematin therapy in porphyric attacks

- Summary
- Subjects
- Metrics

Abstract

We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favor able clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.

Related Organizations

University of Minnesota Morris
United States
Allina Health
United States
Abbott Northwestern Hospital
United States

Keywords

Porphyrias, Hemin, Humans, Heme

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	36
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%